India, April 9 -- Galmed Pharmaceuticals Ltd. (GLMD) shares surged 57.40 percent, gaining $0.3573 to $0.9798 on Thursday, after the company announced a breakthrough brain-penetrating formulation of its lead drug candidate Aramchol for central nervous system diseases.
The stock is currently trading at $0.9798 versus its previous close of $0.6225, after opening at $1.1600 on the Nasdaq. Shares traded in a range of $0.9770 to $1.2600 during the session, with volume reaching 116.71 million shares, sharply above the average daily volume of 50,165.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The company said the new lipid nanoparticle formulation, developed with Barcode Nanotech, is designed to help Ara...